Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Dapagliflozin leads to improved vascular function in the micro- and macrocirculation by action on various cardiovascular risk factors, in particular by effectively controlling hyperglycemia, arterial hypertension and reducing whole sodium content amongst others.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Erlangen-Nürnberg Medical School
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

1. Type 2 diabetes

2. HbA1c > 6.5%

3. age > 18 years

4. male and females

Exclusion Criteria:

1. age > 75 years

2. HbA1c > 10 %,

3. reduced renal function (eGFR < 60 ml/min/1.73 m²).

4. insulin therapy, or any antidiabetic medication other than metformin.

5. uncontrolled hypertension (> 180/>110 mmHg)

6. cardiovascular event within the last 3 months

7. Use of loop diuretics